Aware Super Pty Ltd as trustee of Aware Super Makes New $29.71 Million Investment in Incyte Corporation $INCY

Posted by Francis Steltz on Jul 17th, 2026

Aware Super Pty Ltd as trustee of Aware Super bought a new stake in shares of Incyte Corporation (NASDAQ:INCY – Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 315,637 shares of the biopharmaceutical company’s stock, valued at approximately $29,708,000.

Other hedge funds have also recently modified their holdings of the company. Elyxium Wealth LLC purchased a new stake in shares of Incyte in the fourth quarter worth approximately $28,000. Smithfield Trust Co boosted its holdings in Incyte by 135.0% during the 4th quarter. Smithfield Trust Co now owns 282 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 162 shares during the period. MUFG Securities EMEA plc purchased a new position in Incyte during the 2nd quarter valued at $32,000. CYBER HORNET ETFs LLC bought a new position in Incyte in the 2nd quarter valued at $33,000. Finally, Leonteq Securities AG bought a new position in Incyte in the 4th quarter valued at $35,000. Institutional investors own 96.97% of the company’s stock.

Analysts Set New Price Targets

INCY has been the topic of a number of recent analyst reports. TD Cowen reiterated a “hold” rating on shares of Incyte in a research note on Tuesday, June 9th. Barclays boosted their target price on shares of Incyte from $117.00 to $134.00 and gave the company an “overweight” rating in a research note on Tuesday. Citigroup restated a “market perform” rating on shares of Incyte in a report on Wednesday. Truist Financial raised their price target on shares of Incyte from $103.00 to $105.00 and gave the stock a “hold” rating in a research note on Monday, June 22nd. Finally, Royal Bank Of Canada lifted their price objective on shares of Incyte from $95.00 to $99.00 and gave the company a “sector perform” rating in a report on Tuesday, July 7th. Eight equities research analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the stock. According to data from MarketBeat, Incyte has an average rating of “Hold” and a consensus price target of $109.95.

Check Out Our Latest Stock Report on INCY

Incyte Stock Performance

Shares of Incyte stock opened at $116.65 on Friday. The firm has a market cap of $23.30 billion, a P/E ratio of 16.48, a P/E/G ratio of 1.05 and a beta of 0.76. The company has a current ratio of 3.68, a quick ratio of 3.60 and a debt-to-equity ratio of 0.01. Incyte Corporation has a 12 month low of $67.17 and a 12 month high of $118.97. The stock’s fifty day moving average price is $104.61 and its 200-day moving average price is $100.92.

Incyte (NASDAQ:INCY – Get Free Report) last released its quarterly earnings data on Tuesday, April 28th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts’ consensus estimates of $1.38 by $0.43. Incyte had a net margin of 26.71% and a return on equity of 26.66%. The company had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.22 billion. During the same period in the prior year, the firm earned $1.16 earnings per share. The firm’s revenue for the quarter was up 20.9% compared to the same quarter last year. On average, equities research analysts expect that Incyte Corporation will post 6.61 earnings per share for the current fiscal year.

About Incyte

(Free Report)

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.